Latest CAXTON CORP Stock Portfolio
$19.73Million– No. of Holdings #12
CAXTON CORP Performance:
2024 Q2: 12.94%YTD: 22.39%2023: 67.85%
Performance for 2024 Q2 is 12.94%, and YTD is 22.39%, and 2023 is 67.85%.
About CAXTON CORP and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, CAXTON CORP reported an equity portfolio of $19.7 Millions as of 30 Jun, 2024.
The top stock holdings of CAXTON CORP are XERS, RZLT, SPY. The fund has invested 58.3% of it's portfolio in XERIS BIOPHARMA HOLDINGS INC and 28.7% of portfolio in REZOLUTE INC.
They significantly reduced their stock positions in ABIVAX SA. CAXTON CORP opened new stock positions in CONTEXT THERAPEUTICS INC (CNTX). The fund showed a lot of confidence in some stocks as they added substantially to LEXEO THERAPEUTICS INC, MIND MEDICINE INC (MNMD) and SPDR S&P 500 ETF TR (SPY).
The top stock holdings of CAXTON CORP are XERS, RZLT, SPY. The fund has invested 58.3% of it's portfolio in XERIS BIOPHARMA HOLDINGS INC and 28.7% of portfolio in REZOLUTE INC.
They significantly reduced their stock positions in ABIVAX SA. CAXTON CORP opened new stock positions in CONTEXT THERAPEUTICS INC (CNTX). The fund showed a lot of confidence in some stocks as they added substantially to LEXEO THERAPEUTICS INC, MIND MEDICINE INC (MNMD) and SPDR S&P 500 ETF TR (SPY).
CAXTON CORP Equity Portfolio Value
Last Reported on: 14 Aug, 2024
CAXTON CORP Annual Return Estimates Vs S&P 500
Our best estimate is that CAXTON CORP made a return of 12.94% in the last quarter. In trailing 12 months, it's portfolio return was 22.43%.
New Buys
| Ticker | $ Bought |
|---|---|
| context therapeutics inc | 36,899 |
New stocks bought by CAXTON CORP
Additions
| Ticker | % Inc. |
|---|---|
| lexeo therapeutics inc | 72.99 |
| kyverna therapeutics inc | 45.03 |
| mind medicine inc | 4.53 |
| spdr s&p 500 etf tr | 0.7 |
| berkshire hathaway inc del | 0.59 |
Additions to existing portfolio by CAXTON CORP
Reductions
| Ticker | % Reduced |
|---|---|
| abivax sa | -12.07 |
CAXTON CORP reduced stake in above stock
Sold off
Sector Distribution
CAXTON CORP has about 89.5% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 89.5 |
| Others | 10.5 |
Market Cap. Distribution
CAXTON CORP has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 59.4 |
| MICRO-CAP | 29.3 |
| UNALLOCATED | 10.5 |
Stocks belong to which Index?
About 58.6% of the stocks held by CAXTON CORP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 58.6 |
| Others | 41.4 |
CAXTON CORP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of CAXTON CORP
CAXTON CORP has 12 stocks in it's portfolio. MTEM proved to be the most loss making stock for the portfolio. RZLT was the most profitable stock for CAXTON CORP last quarter.
Last Reported on: 14 Aug, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACET | adicet bio inc | 0.11 | 17,488 | 21,160 | unchanged | 0.00 | ||
| CMPX | compass therapeutics inc | 0.22 | 43,465 | 43,465 | unchanged | 0.00 | ||
| CNTX | context therapeutics inc | 0.19 | 18,403 | 36,899 | new | |||
| MNMD | mind medicine inc | 1.11 | 30,383 | 219,059 | added | 4.53 | ||
| MTEM | molecular templates inc | 0.80 | 136,866 | 157,396 | unchanged | 0.00 | ||
| RZLT | rezolute inc | 28.74 | 1,318,970 | 5,671,560 | unchanged | 0.00 | ||
| SPY | spdr s&p 500 etf tr | 5.15 | 1,869 | 1,016,920 | added | 0.7 | ||
| XERS | xeris biopharma holdings inc | 58.31 | 5,113,350 | 11,505,000 | unchanged | 0.00 | ||
| berkshire hathaway inc del | 2.11 | 1,025 | 417,070 | added | 0.59 | |||
| lexeo therapeutics inc | 1.45 | 17,851 | 286,331 | added | 72.99 | |||
| abivax sa | 0.93 | 13,900 | 183,760 | reduced | -12.07 | |||
| kyverna therapeutics inc | 0.87 | 22,981 | 172,359 | added | 45.03 | |||